• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intel and GE win FDA clearance for virtual care platform | Regulatory roundup

Intel and GE win FDA clearance for virtual care platform | Regulatory roundup

March 3, 2011 By MassDevice staff

Clearances roundup

Intel Corp. (NSDQ:INTC) and General Electric Co. (NYSE:GE) joint venture Intel-GE Care Innovations LLC won 510(k) clearance from the Food & Drug Administration for a virtual care coordination platform.

The clearance for the news system, called Intel Health Guide Express, brings the companies another step closer to making the product available for off-the-shelf personal computers.

The system is designed to help healthcare professionals and patients manage chronic care by making vital signs collection, interactive patient health sessions, video conferencing capabilities, and multimedia educational content available on consumer PCs, according to the companies.

"With this new platform, Intel-GE Care Innovations facilitates greater care coordination that gives healthcare organizations the ability to innovate and provide customized care," Intel-GE Care Innovations CEO Louis Burns said in prepared remarks.

Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.

  • Ventus lands CE Mark for Provent sleep apnea therapy
    Belmont, Calif.-based Ventus Medical Inc. received CE Mark for its Provent sleep apnea therapy. "We are pleased to accomplish this important regulatory milestone. Receiving CE Mark for Provent Therapy will facilitate our international commercialization strategy and allow us to launch this product in selected countries over the next several months," CEO Peter Wyles said in prepared remarks. "There is a clear need for therapeutic options other than [continuous positive airway pressure] and Provent Therapy represents an attractive new alternative," he said.
    Read more
  • Meridian Bioscience gets FDA clearance for its illumigene C. difficile test for pediatrics
    Cincinnati, Ohio-based Meridian Bioscience Inc. (NSDQ:VIVO) won FDA 510(k) clearance for a new pediatric claim for its illumigene C. difficile (Clostridium difficile) molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular test is designed to target the region of the C. difficile DNA that is presented in all toxin A and/or toxin B producing strains. The illumigene test provides highly accurate results in under an hour. Meridian Bioscience’s illumigene test is the only C. difficile test that is cleared by the FDA for use on children under the age of two.
    Read more
  • Vasomedical positioned to seek increased reimbursement for EECP therapy
    Westbury, N.Y.-based Vasomedical Inc. (OTC:VASO) announced the execution of a definitive agreement with Edgary Consultants LLC to facilitate its effort to broaden reimbursement coverage of EECP therapy, a proprietary technology for the treatment of certain cardiovascular diseases, with commercial third-party payers as well as Centers for Medicare and Medicaid Services (CMS). EECP therapy received initial coverage by Medicare in 1999.
    Read more
  • MP Biomedicals wins approval for HIV test in Brazil
    MP Biomedicals Asia Pacific PTE LTD, a subsidiary of MP Biomedicals LLC, received approval from The National Health Surveillance Agency (ANVISA) to market its HIV Blot 2.2, HIV Blot 1.3, HCV Blot 3.0 and HTLV – I/II ELISA 4.0 diagnostic tests in Brazil. This is MP Biomedicals second approval from ANVISA, with the first coming in August of 2010 when the company’s Assure Dengue IgA rapid test was cleared for marketing. MP Biomedicals said it will work closely with its distributors and with the blood centers in Brazil to introduce these diagnostic products.
    Read more

Filed Under: 510(k), News Well, Software / IT Tagged With: Gift Bans, Intel Corp., Meridian Bioscience Inc., MP Biomedicals LLC, Vasomedical Inc., Ventus Medical Inc.

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy